The treatment landscape for HER2-positive early breast cancer is evolving rapidly after the latest US Food and Drug Administration approval of ENHERTU® (fam-trastuzumab deruxtecan-nxki). Developed through a collaboration between AstraZeneca and Daiichi Sankyo, ENHERTU has now secured approval for two additional indications in early-stage HER2-positive breast cancer.
These approvals represent a major milestone in breast cancer care because they bring ENHERTU into the curative-intent setting for patients diagnosed with Stage II and Stage III HER2-positive breast cancer. The decisions are based on results from the Phase III DESTINY-Breast11 and DESTINY-Breast05 clinical trials, which demonstrated meaningful improvements in treatment outcomes.
The FDA approved ENHERTU in both the neoadjuvant and adjuvant treatment settings for HER2-positive early breast cancer.
In the neoadjuvant setting, ENHERTU followed by taxane, trastuzumab, and pertuzumab (THP) is now approved for adults with HER2-positive Stage II or Stage III breast cancer before surgery.
In the adjuvant setting, ENHERTU is approved for adults with HER2-positive breast cancer who still have residual invasive disease after receiving trastuzumab-based and taxane-based treatment before surgery.
This expanded approval significantly strengthens ENHERTU’s role across multiple stages of HER2-positive breast cancer management.
HER2-positive breast cancer is considered one of the more aggressive forms of breast cancer. HER2 overexpression can accelerate tumor growth and increase the risk of recurrence.
Although modern HER2-targeted therapies have improved survival rates, recurrence remains a serious concern. Experts estimate that up to one in four patients with HER2-positive early breast cancer may experience disease recurrence despite existing treatments.
Early intervention is critical because outcomes decline significantly once cancer progresses to metastatic disease. This is why oncologists continue searching for therapies that improve pathologic complete response rates and reduce recurrence risk.
The DESTINY-Breast11 Phase III trial evaluated ENHERTU as part of neoadjuvant therapy before surgery.
Results showed that ENHERTU followed by THP achieved a pathologic complete response rate of 67.3%, compared with 56.3% in patients receiving the standard dose-dense chemotherapy regimen known as ddAC-THP.
This improvement of more than 11% is clinically significant because achieving pathologic complete response often predicts improved long-term survival outcomes.
The trial also reported relatively low event-free survival and overall survival events at the time of analysis, supporting the therapy’s effectiveness in earlier-stage disease management.
The DESTINY-Breast05 trial focused on patients who had residual invasive disease following neoadjuvant therapy.
ENHERTU reduced the risk of invasive disease recurrence or death by 53% when compared with trastuzumab emtansine (T-DM1), which has been a commonly used standard treatment in this setting.
At three years, 92.4% of patients receiving ENHERTU remained alive and free from invasive disease, compared with 83.7% of patients treated with T-DM1.
These findings suggest ENHERTU could become a preferred adjuvant treatment option for high-risk HER2-positive early breast cancer patients.
Leading oncology specialists have welcomed the FDA approvals as a major advancement for breast cancer care.
Dr. Shanu Modi of Memorial Sloan Kettering Cancer Center highlighted the importance of improving outcomes as early as possible to reduce recurrence risks and improve long-term survival.
Executives from AstraZeneca and Daiichi Sankyo also emphasized that the approvals reinforce ENHERTU’s position as a foundational treatment in HER2-positive breast cancer across early and metastatic settings.
Patient advocacy organizations such as Susan G. Komen also praised the approvals for expanding treatment choices and offering renewed hope to patients and families facing aggressive breast cancer diagnoses.
ENHERTU is a HER2-directed antibody drug conjugate, often called an ADC. It combines a HER2-targeting monoclonal antibody with a chemotherapy payload linked together using advanced drug delivery technology.
This design allows the treatment to target HER2-expressing cancer cells more precisely while delivering a potent anti-cancer agent directly into tumor cells.
ENHERTU has already transformed treatment approaches in metastatic HER2-positive breast cancer and HER2-low breast cancer. The latest approvals expand its use into earlier disease stages where cure may still be achievable.
While ENHERTU offers promising clinical benefits, safety monitoring remains essential.
One of the most important safety concerns is interstitial lung disease (ILD) or pneumonitis, which can be severe and potentially fatal. Patients receiving ENHERTU should be carefully monitored for symptoms such as cough, breathing difficulties, fever, or worsening respiratory issues.
Other common side effects include:
Healthcare professionals must also monitor cardiac function and blood counts during treatment.
Patients who are pregnant or may become pregnant should avoid ENHERTU because exposure during pregnancy may cause fetal harm.
ENHERTU is already approved in more than 95 countries for several HER2-positive cancer indications, including metastatic breast cancer and gastric cancer.
The treatment is also under investigation across a wide range of HER2-targetable cancers through an extensive global clinical development program.
The latest FDA approvals further strengthen ENHERTU’s position as one of the most important targeted therapies in modern oncology.
The expanded FDA approval of ENHERTU signals a new era in HER2-positive early breast cancer care. By improving pathologic complete response rates and reducing recurrence risk, ENHERTU may help more patients achieve long-term remission and potentially curative outcomes.
As additional clinical data emerge and regulatory reviews continue worldwide, ENHERTU is expected to play an even greater role in personalized breast cancer treatment strategies.
For patients and clinicians alike, these approvals represent meaningful progress in the ongoing effort to improve survival and quality of life in HER2-positive breast cancer.
AstraZeneca Official Website
This article is intended for informational and educational purposes only and should not be considered medical advice. Patients should consult qualified healthcare professionals regarding diagnosis, treatment decisions, and potential risks associated with ENHERTU or any cancer therapy. Clinical outcomes may vary depending on individual patient circumstances.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.